Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

NCT06123468 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Esophagogastric Adenocarcinoma

Interventions

DRUG: Sacituzumab govitecan

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]